Investor Presentaiton

Expanding opportunity Significant capital needs Innovative funding Facilitating M&A Differentiated sourcing Expansion of partnerships validates unique model biohaven ☐ pharmaceuticals bio cryst Cytokinetics ROYALTY PHARMA Capital provided Up to $835m across four transactions Assets acquired Nurtec ODT and zavegepant royalties, commercial launch capital, preferred and common equity Up to $325m across two transactions Orladeyo and BCX9930 royalties and common equity Up to $550m across two transactions Aficamten and omecamtiv mecarbil royalties, common equity and commercial launch capital 40 40

View entire presentation